Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Foghorn Therapeutics Inc. - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
FHTX
Nasdaq
8731
https://foghorntx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Foghorn Therapeutics Inc.
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
- Apr 16th, 2024 11:00 am
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
- Apr 9th, 2024 8:30 pm
Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans
- Apr 9th, 2024 10:34 am
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
- Apr 5th, 2024 11:00 am
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 105.75% as Wall Street Analysts Expect?
- Apr 2nd, 2024 1:55 pm
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
- Mar 26th, 2024 11:00 am
Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's What You Should Know
- Mar 13th, 2024 4:00 pm
Wall Street Analysts Predict a 124.31% Upside in Foghorn Therapeutics Inc. (FHTX): Here's What You Should Know
- Mar 13th, 2024 1:55 pm
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates
- Mar 7th, 2024 1:20 pm
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
- Mar 7th, 2024 12:00 pm
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909
- Mar 5th, 2024 9:48 pm
Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock?
- Feb 28th, 2024 1:29 pm
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
- Feb 28th, 2024 12:00 pm
Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?
- Feb 12th, 2024 7:43 am
Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development
- Feb 9th, 2024 3:02 pm
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
- Feb 8th, 2024 12:00 pm
With 39% stake, Foghorn Therapeutics Inc. (NASDAQ:FHTX) seems to have captured institutional investors' interest
- Jan 11th, 2024 10:34 am
Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024
- Jan 8th, 2024 12:00 pm
Foghorn Therapeutics Announces CFO Departure
- Jan 3rd, 2024 9:05 pm
Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's Why
- Dec 26th, 2023 5:00 pm
Scroll